Latest news

• NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

  The limited recommendation takes into account that the Tobi Podhaler and Colobreathe are dry powder versions of already available nebulised products. ... form. The Tobi Podhaler should only be used in cystic fibrosis patients for whom nebulised

• NICE backs two cystic fibrosis treatments for NHS use

  NICE backs two cystic fibrosis treatments for NHS use. Novartis’ Tobi Podhaler and Forest’ s Colobreathe recommended at discounted price. ... Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS

• NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

  NICE backs Novartis’ Tobi Podhaler in cystic fibrosis. But draft guidance doesn't recommend Forest’ s Colobreathe. ... In addition, the Tobi Podhaler should only be available for patients unable to use nebulised colistimethate, or for whom nebulised

• FDA panel backs Novartis' updated cystic fibrosis drug

  Novartis' current tobramycin product TOBI has been the standard of care of this infection in CF since it was launched in 1997, but is delivered using a nebuliser machine which is ... The new product is already approved in the EU and Canada, where it is